Phase 1 N=30 A Study of Galcanezumab (LY2951742) in Healthy Chinese Participants
Healthy
Primary: Pharmacokinetics: Maximum Concentration (Cmax) of Galcanezumab — 12.6; 27.2 micrograms per milliliter (μg/mL)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=51 Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer
Malignant Neoplasm of Breast
Primary: Changes in QTcF After Treatment With DS-8201a in Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer — 3; 0 Participants
Phase 1 N=18 Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma
Unresectable Stage IIIB-IV Malignant Melanoma
Primary: Number of Participants Who Experienced One or More Dose Limiting Toxicities (DLTs) — 0 Participants
Phase 1 N=8 A Clinical Study to Measure the Effect of OP-101 After Being Administered Subcutaneous in Healthy Volunteers
Healthy
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events — 2; 3; 0; 0 Participants
Phase 1 N=12 DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein
Adenocarcinoma, Gastric · Neoplasm, Breast
Primary: Treatment-emergent Adverse Events Following Treatment With DS-8201a (Trastuzumab Deruxtecan) — 12; 12; 7; 6 Participants
Phase 1 N=40 Study of DS-8201a for Participants With Advanced Solid Malignant Tumors
Neoplasm Metastasis
Primary: Pharmacokinetic Parameter of Maximum (Peak) Observed Serum Concentration (Cmax) Following Treatment With DS-8201a and Ritonavir - Cohort 1 — 133; 140; 121; 126 ug/mL
Phase 1 N=36 Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
Metastatic Triple Negative Breast Cancer · Metastatic Colorectal Cancer
Primary: Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT) — 0; 3 Participants
Phase 1 N=21 A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast
Healthy Subjects
Primary: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUCt) of Apremilast — 3070; 2940; 850 ng*h/mL
Phase 1 N=30 Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults
Malaria
Primary: Number of Participants With Solicited or Unsolicited Symptoms Reporting During the Post-vaccination Period — 10; 10; 9; 10 participants
Phase 1 N=8 111In-ch806 in Patients With Advanced Tumours Expressing the 806 Antigen
Neoplasms
Primary: Number of Patients With Adverse Events — 2; 2; 2; 2 Participants
Phase 1 N=18 Relative Bioavailability of BI 1467335 Tablet and Oral Solution, and Food Effect on Tablet in Healthy Male Subjects
Healthy Volunteers
Primary: AUC0-tz of BI 1467335 — 3.90; 2.24; 2.49 nanomole*hour/Liter (nmol*h/L)
Phase 1 N=36 To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1467335 Following Multiple Dose Administration Over 28 Days
Healthy
Primary: Number of Subjects With Investigator Defined Drug-related Adverse Events — 3; 4; 6; 4 Participants
Phase 1 N=16 This Study Tests BI 1467335 in Healthy Male Volunteers. The Study Tests How Different Doses of BI 1467335 Are Taken up and Handled by the Body
Healthy
Primary: Fraction of [14C]-Radioactivity Excreted in Urine as Percentage of the Administered Oral Dose Over the Time Interval From 0 to the Last Quantifiable Time Point…
Phase 1 N=10 A Study in Healthy Men to Test the Effects of Different Doses of BI 1467335 on MAO-B Activity in the Brain.
Healthy
Primary: Percentage Reduction in Whole Brain Monoamine Oxidase (MAO)-B Availability Assessed by Positron Emission Tomography (PET) Imaging — 72.58; 2.43 Percent reduction
Phase 1 N=21 A Study of TAS-205 for Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
Primary: Incidence of Adverse Events — 0; 3; 1; 1 participants